512
Views
3
CrossRef citations to date
0
Altmetric
Original Research Articles

Molecular characterization of HCV in a Swedish county over 8 years (2002–2009) reveals distinct transmission patterns

, PhD, , MD, , PhD, Associate Professor, , MD, Professor, , PhD, , BSc, , MD, County Medical Officer, , PhD, Associate Professor, , PhD & , PhD show all
Article: 30670 | Received 12 Dec 2015, Accepted 13 Jan 2016, Published online: 05 Feb 2016

References

  • WHO. Hepatitis C: fact sheet no. 164. 2012; Geneva. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/ (cited 30 December 2015]..
  • Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29(Suppl 1): 74–81.
  • Duberg AS, Blach S, Falconer K, Kaberg M, Razavi H, Aleman S. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol. 2015; 50: 233–44.
  • Duberg AS, Pettersson H, Aleman S, Blaxhult A, Daviethsdottir L, Hultcrantz R, etal. The burden of hepatitis C in Sweden: a national study of inpatient care. J Viral Hepat. 2011; 18: 106–118.
  • Choo QL, Kuo G, Weiner A, Wang KS, Overby L, Bradley D, etal. Identification of the major, parenteral non-A, non-B hepatitis agent (hepatitis C virus) using a recombinant cDNA approach. Semin Liver Dis. 1992; 12: 279–88.
  • Duberg A, Janzon R, Back E, Ekdahl K, Blaxhult A. The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill . 2008. pii: 18882.
  • Jackowiak P, Kuls K, Budzko L, Mania A, Figlerowicz M, Figlerowicz M. Phylogeny and molecular evolution of the hepatitis C virus. Infect Genet Evol. 2014; 21: 67–82.
  • Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, etal. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61: 77–87.
  • Trimbitas RD, Serghini FZ, Lazaar F, Baha W, Foullous A, Essalhi M, etal. The “hidden” epidemic: a snapshot of Moroccan intravenous drug users. Virol J. 2014; 11: 43.
  • Nakano T, Lau GM, Lau GM, Sugiyama M, Mizokami M. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 2012; 32: 339–45.
  • Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, etal. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014; 59: 318–27.
  • Ampuero J, Romero-Gomez M, Reddy KR. Review article: HCV genotype 3 – the new treatment challenge. Aliment Pharmacol Ther. 2014; 39: 686–98.
  • Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 369: 678–9.
  • Li HC, Lo SY. Hepatitis C virus: virology, diagnosis and treatment. World J Hepatol. 2015; 7: 1377–89.
  • Westin J, Lindh M, Lagging LM, Norkrans G, Wejstal R. Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings. Scand J Infect Dis. 1999; 31: 355–8.
  • Lindh M, Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR. J Clin Virol. 2005; 34: 108–14.
  • Lidman C, Norden L, Kaberg M, Kall K, Franck J, Aleman S, etal. Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender. Scand J Infect Dis. 2009; 41: 679–84.
  • Danielsson A, Palanisamy N, Golbob S, Yin H, Blomberg J, Hedlund J, etal. Transmission of hepatitis C virus among intravenous drug users in the Uppsala region of Sweden. Infect Ecol Epidemiol. 2014; 4 , 22251, doi: http://dx.doi.org/10.3402/iee.v4.22251 .
  • Bruggmann P, Berg T, Ovrehus AL, Moreno C, Brandao Mello CE, Roudot-Thoraval F, etal. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat. 2014; 21(Suppl 1): 5–33.
  • Kalinina O, Norder H, Vetrov T, Zhdanov K, Barzunova M, Plotnikova V, etal. Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J Med Virol. 2001; 65: 517–24.
  • Norder H, Bergstrom A, Uhnoo I, Alden J, Weiss L, Czajkowski J, etal. Confirmation of nosocomial transmission of hepatitis C virus by phylogenetic analysis of the NS5-B region. J Clin Microbiol. 1998; 36: 3066–9. [PubMed Abstract] [PubMed CentralFull Text].
  • Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010; 59: 307–21.
  • Anisimova M, Gil M, Dufayard JF, Dessimoz C, Gascuel O. Survey of branch support methods demonstrates accuracy, power, and robustness of fast likelihood-based approximation schemes. Syst Biol. 2011; 60: 685–99.
  • Folch C, Casabona J, Espelt A, Majo X, Merono M, Gonzalez V, etal. Gender differences in HIV risk behaviours among intravenous drug users in Catalonia, Spain. Gac Sanit. 2013; 27: 338–43.
  • Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon. Virol J. 2010; 7: 96.
  • Raptopoulou M, Touloumi G, Tzourmakliotis D, Nikolopoulou G, Dimopoulou M, Giannoulis G, etal. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia. 2011; 15: 26–31. [PubMed Abstract] [PubMed CentralFull Text].
  • Calado RA, Rocha MR, Parreira R, Piedade J, Venenno T, Esteves A. Hepatitis C virus subtypes circulating among intravenous drug users in Lisbon, Portugal. J Med Virol. 2011; 83: 608–15.
  • Stamenkovic G, Zerjav S, Velickovic ZM, Krtolica K, Samardzija VL, Jemuovic L, etal. Distribution of HCV genotypes among risk groups in Serbia. Eur J Epidemiol. 2000; 16: 949–54.
  • Vince A, Iscic-Bes J, Zidovec Lepej S, Baca-Vrakela I, Bradaric N, Kurelac I, etal. Distribution of hepatitis C virus genotypes in Croatia – a 10 year retrospective study of four geographic regions. Coll Antropol. 2006; 30(Suppl 2): 139–43. [PubMed Abstract].
  • Schroter M, Zollner B, Laufs R, Feucht HH. Changes in the prevalence of hepatitis C virus genotype among injection drug users: a highly dynamic process. J Infect Dis. 2004; 190: 1199–200.
  • Treso B, Takacs M, Dencs A, Dudas M, Par A, Rusvai E. Molecular epidemiology of hepatitis C virus genotypes and subtypes among injecting drug users in Hungary. Euro Surveill. 2013; 18 pii: 20639.
  • Tallo T, Norder H, Tefanova V, Krispin T, Schmidt J, Ilmoja M, etal. Genetic characterization of hepatitis C virus strains in Estonia: fluctuations in the predominating subtype with time. J Med Virol. 2007; 79: 374–82.
  • Ngui SL, Brant L, Markov PV, Tung JP, Pybus OG, Teo CG, etal. Hepatitis C virus genotype 4 in England: diversity and demographic associations. J Med Virol. 2015; 87: 417–23.
  • Lagging M, Duberg AS, Wejstal R, Weiland O, Lindh M, Aleman S, etal. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scand J Infect Dis. 2012; 44: 502–21.
  • Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, etal. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol. 2006; 78: 1296–303.
  • Pybus OG, Cochrane A, Holmes EC, Simmonds P. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol. 2005; 5: 131–9.
  • Kylefjord H, Danielsson A, Sedig S, Belda O, Wiktelius D, Vrang L, etal. Transient replication of a hepatitis C virus genotype 1b replicon chimera encoding NS5A-5B from genotype 3a. J Virol Methods. 2014; 195: 156–63.
  • Terrault NA, Dodge JL, Murphy EL, Tavis JE, Kiss A, Levin TR, etal. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013; 57: 881–9.
  • Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, etal. Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?. Liver Int. 2015; 35: 2384–91.
  • Widell A, Christensson B, Wiebe T, Schalen C, Hansson HB, Allander T, etal. Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service. Ann Intern Med. 1999; 130: 130–4.
  • Waldenstrom J, Konar J, Ekermo B, Norder H, Lagging M. Neonatal transfusion-transmitted hepatitis C virus infection following a pre-seroconversion window-phase donation in Sweden. Scand J Infect Dis. 2013; 45: 796–9.
  • Choudhary MC, Natarajan V, Pandey P, Gupta E, Sharma S, Tripathi R, etal. Identification of Indian sub-continent as hotspot for HCV genotype 3a origin by Bayesian evolutionary reconstruction. Infect Genet Evol. 2014; 28: 87–94.
  • Paintsil E, Verevochkin SV, Dukhovlinova E, Niccolai L, Barbour R, White E, etal. Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction. 2009; 104: 1881–90.
  • Aitken CK, McCaw RF, Bowden DS, Tracy SL, Kelsall JG, Higgs PG, etal. Molecular epidemiology of hepatitis C virus in a social network of injection drug users. J Infect Dis. 2004; 190: 1586–95.
  • Magiorkinis G, Sypsa V, Magiorkinis E, Paraskevis D, Katsoulidou A, Belshaw R, etal. Integrating phylodynamics and epidemiology to estimate transmission diversity in viral epidemics. PLoS Comput Biol. 2013; 9: e1002876.
  • Samimi-Rad K, Nasiri Toosi M, Masoudi-Nejad A, Najafi A, Rahimnia R, Asgari F, etal. Molecular epidemiology of hepatitis C virus among injection drug users in Iran: a slight change in prevalence of HCV genotypes over time. Arch Virol. 2012; 157: 1959–65.
  • Li C, Lu L, Murphy DG, Negro F, Okamoto H. Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e. J Gen Virol. 2014; 95: 1677–88.
  • Akkarathamrongsin S, Hacharoen P, Tangkijvanich P, Theamboonlers A, Tanaka Y, Mizokami M, etal. Molecular epidemiology and genetic history of hepatitis C virus subtype 3a infection in Thailand. Intervirology. 2013; 56: 284–94.
  • Hillgren K, Sarkar K, Elofsson S, Britton S. [Widespread risk behavior among injecting drug users. Over 80 percent HCV-infected – 7 percent have HIV, as demonstrated by the first baseline study]. Lakartidningen. 2012; 109: 1221–5. [PubMed Abstract].